Can PCOD Be Cured Naturally? What Restores Ovulation

No. PCOD and PCOS are the same condition, and neither has a cure. The World Health Organization's fact sheet says so in one line: there is currently no cure for PCOS, but lifestyle changes, medications and fertility treatments can reduce symptoms, increase fertility rates and protect longer-term health. The 2023 international guideline agrees in its own register — rec 1.7.1 says a diagnosis of PCOS could be considered as enduring or lifelong.

That sounds worse than it is, and it is worth separating two questions that get collapsed into one. A great many women hear a PCOS diagnosis as "I will not be able to have children". The honest answer is considerably better than that: PCOS is the most common cause of anovulation worldwide, according to WHO, and not ovulating is one of the more treatable reasons for not conceiving.

• Does the condition go away — no, and no treatment claims it does.
• Do symptoms improve — often substantially.
• Does ovulation return — frequently, and that is the part that matters for conceiving.
• Does it still need attention afterwards — yes. WHO calls PCOS a chronic metabolic condition that persists beyond the reproductive years.

Anything sold as a cure — a diet, a supplement, a protocol, a detox — is making a claim neither WHO nor the guideline supports.

Not as a substitute for treatment, and the best randomised evidence is a caution against delay rather than an endorsement of it. The LIFEstyle trial randomised 577 infertile women with a BMI of 29 or above to either a six-month lifestyle programme followed by 18 months of fertility treatment, or to 24 months of prompt treatment. The lifestyle group lost more weight — 4.4 kg against 1.1 kg — and had fewer healthy term births: 27.1% against 35.2%, a rate ratio of 0.77 with a confidence interval of 0.60 to 0.99.

Read that carefully, because it is misread in both directions. It is not a finding that losing weight is harmful. The trial compared strategies, not weights, and the prompt-treatment arm had six extra months of treatment inside the same 24-month window. Roughly a fifth of the lifestyle group — 21.8% of 289 women — discontinued it. And the cohort was infertile women with a high BMI, not a PCOS cohort, so it bears on the "lose weight first" instruction rather than on PCOS specifically.

What the 2023 guideline itself asks for is looser than the diet sheets suggest. Lifestyle change is recommended for everyone with PCOS, for metabolic health including central adiposity and lipid profile (rec 3.1.1). But rec 3.1.5 states there are benefits even in the absence of weight loss; rec 3.1.6 asks for a tailored energy deficit rather than a fixed figure; and rec 3.4.1 finds no evidence favouring any one type or intensity of exercise. Rec 3.1.7 asks clinicians to be conscious of weight stigma when they raise any of it.

A drug, in most cases, and a specific one. Rec 5.3.1 of the 2023 guideline states letrozole should be the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS with no other infertility factors. Rec 5.4.5.1 places it ahead of clomiphene citrate for ovulation, clinical pregnancy and live birth rates — a reversal of the order that stood for decades. If gonadotrophins come up, they are second-line, after first-line oral induction has failed (rec 5.5.5), and IVF sits third. Our article on how ovulation induction works covers the process, and PCOS and fertility walks the full ladder.

Two things an Indian reader should expect to hear. First, the guideline notes that ovulation induction agents — letrozole, metformin and clomiphene among them — are off-label in many countries, and rec 5.3.2 repeats it for letrozole specifically; where off-label use is permitted the guideline asks clinicians to discuss the evidence and the side effects with you. Second, being offered IVF as an opening move for PCOS is worth a question about what was tried before it.

Not on the strength of a website, and not because someone told you your version is the mild one. That decision belongs with whoever prescribed it, and there are usually reasons in your notes that a general article cannot see.

What the guideline can tell you is where metformin sits. Rec 4.3.1 says metformin alone should be considered in adults with PCOS and a BMI of 25 or above, for anthropometric and metabolic outcomes including insulin resistance, glucose and lipid profiles; rec 4.3.3 allows it below that BMI on limited evidence. Its job is primarily metabolic, not ovulatory. Rec 5.4.1.1 is blunt: if metformin is used alone for anovulatory infertility, women should be informed there are more effective ovulation agents.

Two practical points from rec 4.3.4. Women should be informed that metformin and active lifestyle intervention have similar efficacy — so the two are options to weigh, not a ladder to climb. And long-term use may be associated with low vitamin B12, so monitoring is worth asking about, particularly on a vegetarian diet. We have given no doses here; that is a prescribing decision.

The evidence is weak, and weaker for fertility than for anything else. That is worth saying plainly, because inositol is marketed hard to women with PCOS in India and the marketing is considerably more confident than the guideline.

• For fertility, rec 5.8.1 calls inositol in any form, alone or combined with other therapies, experimental therapy in women with PCOS with infertility, with benefits and risks too uncertain to recommend as a fertility therapy. Rec 5.8.3 adds that side effects and safety are not known.
• For general management, rec 4.7.1 allows it could be considered — noting limited harm and possible improvement in metabolic measures, but limited clinical benefit including in ovulation, hirsutism and weight. Rec 4.7.2 prefers metformin for hirsutism and central adiposity.
• Rec 4.7.4 states specific types, doses or combinations of inositol cannot currently be recommended, for lack of quality evidence — so a product promising a particular ratio is promising more than is known.
• Rec 4.7.5 notes regulation and quality control for supplements can differ from those for pharmaceutical products, and dose and quality may vary between products.

None of that makes inositol forbidden. It makes it a low-confidence option to discuss, not a substitute for a treatment that works.

The gap between what is sold for PCOS and what is recommended for it is unusually wide, and most of it trades on the word natural.

• No supplement has been shown to cure PCOS, and none is presented as curative anywhere in the guideline.
• A normal-weight woman with PCOS is not failing to try hard enough. Rec 3.1.9 addresses her directly.
• Detoxes and hormone-balancing protocols have no guideline support of any kind.
• We could not retrieve any Indian national PCOS guideline while preparing this page, so nothing here is attributed to one.

The reason the absence of a cure matters practically is follow-up. Rec 1.8.2 asks that all women with PCOS be assessed for cardiovascular risk factors, rec 1.8.3 that all of them have a lipid profile at diagnosis regardless of age and BMI, and rec 1.8.4 that blood pressure be measured annually and when planning pregnancy or fertility treatment. A condition managed rather than cured needs someone still managing it in ten years, and that is easier to arrange if nobody was told it had been fixed.